Amneal announces submission of new drug application to the u.s. fda for ipx203 for the treatment of parkinson's disease

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nyse: amrx) today announced it has submitted a new drug application (nda) to the u.s. food and drug administration (fda) for ipx203, a novel, oral formulation of carbidopa/levodopa (cd/ld) extended-release capsules for the treatment of parkinson's disease (pd). the submission is based on results from the pivotal phase 3 rise-pd clinical trial demonstrating more “good on” time compared to immediate-release cd/ld, even when ipx203
AMRX Ratings Summary
AMRX Quant Ranking